5.2 Calcineurin Inhibitors (Tacrolimus vs Cyclosporine)

Comprehensive Summary: Calcineurin Inhibitors — Tacrolimus vs. Cyclosporine

Lecture 5.2 | Prof. Sanjaya Satapathy, MD, FAASLD

1. Main Clinical Topics Discussed

• Mechanism of action of calcineurin inhibitors (CNIs)
• Comparative pharmacology and clinical profiles of tacrolimus vs. cyclosporine
• CNI-associated toxicities (nephrotoxicity, neurotoxicity, metabolic effects)
• Drug-drug interactions via CYP3A4 pathway
• Distinguishing CNI toxicity from allograft rejection
• CNI modification and conversion strategies in post-transplant management

2. Key Learning Points, Guidelines, and Recommendations

Mechanism of Action

• CNIs inhibit calcineurin phosphatase, preventing dephosphorylation of NFAT (Nuclear Factor of Activated T-cells)
• Phosphorylated NFAT cannot enter the nucleus → reduced IL-2 transcription → suppressed T-cell activation and proliferation
• Tacrolimus binds FKBP-12 (FK-binding protein)
• Cyclosporine binds cyclophilin
• Both drug-protein complexes converge on calcineurin inhibition — identical downstream immunologic effect, different intracellular binding partners
• Board pearl: CNIs suppress IL-2 *production*; they are T-cell targeted agents and do not directly inhibit antibody production

Why Tacrolimus Is Preferred

• Lower acute rejection rates compared to cyclosporine (supported by multiple studies)
• Fewer cosmetic side effects (avoids gingival hyperplasia and hirsutism)
• Superior long-term graft outcomes in most transplant populations

3. Specific Clinical Data, Toxicity Profiles, and Study Results

Tacrolimus Toxicity Profile

• Nephrotoxicity: Afferent arteriolar vasoconstriction → reduced GFR → rising creatinine; can occur even at therapeutic levels; dose-dependent; early injury is hemodynamic (not structural)
• Neurotoxicity: Fine tremor (most common, dose-related) → headache → confusion → seizures → PRES (Posterior Reversible Encephalopathy Syndrome); presents with seizures, visual changes, altered mental status, posterior white matter edema on MRI
• Hyperkalemia: Impaired distal tubular potassium excretion
• Hypomagnesemia: Increased renal magnesium wasting; can potentiate neurotoxicity and seizure risk
• Hypertension: Renal vasoconstriction
• Post-transplant diabetes mellitus (PTDM): Direct pancreatic beta-cell toxicity + insulin resistance (compounded by steroids); tacrolimus carries higher PTDM risk than cyclosporine

Cyclosporine Toxicity Profile

• Shared with tacrolimus: Nephrotoxicity, hypertension, hyperkalemia
• Distinctive features:

- Gingival hyperplasia

- Hirsutism

- Greater hyperlipidemia (elevated LDL) compared to tacrolimus

- More hypertension than tacrolimus

- Lower neurotoxicity and PTDM risk than tacrolimus

Key Comparative Summary Table (Board-Focused)

CNI Nephrotoxicity — Key Diagnostic Pattern

• Early: Rising creatinine + bland urinalysis (no proteinuria, no casts) =